Skip to main content

Metagenomi Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

MGX$0.70-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,
2024202320242023
Collaboration revenue$11,514$12,363$42,681$32,357
Operating expenses:
Research and development26,25626,83786,01569,648
General and administrative7,6417,92124,94421,005
Total operating expenses33,89734,758110,95990,653
Loss from operations(22,383)(22,395)(68,278)(58,296)
Other income (expense):
Interest income3,6163,86611,52611,836
Change in fair value of long-term investments(2,055)—(2,055)2,870
Other expense, net(57)(85)(158)(70)
Total other income, net1,5043,7819,31314,636
Net loss before benefit (provision) for income taxes(20,879)(18,614)(58,965)(43,660)
Benefit (provision) for income taxes2,106(1,206)4,305(5,301)
Net loss$(18,773)$(19,820)$(54,660)$(48,961)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale marketable securities1,904701,736(85)
Comprehensive loss$(16,869)$(19,750)$(52,924)$(49,046)
Net loss per share attributable to common stockholders, basic and diluted$(0.51)$(5.82)$(1.73)$(14.38)
Weighted average common shares outstanding, basic and diluted36,766,3093,404,58531,601,8253,404,585
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.